# Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

> **NCT00971425** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 145 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Pandemrix (GSK investigational influenza GSK2340272A vaccine)
- **BIOLOGICAL:** Fluarix™
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00971425
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-08
- **Primary completion:** 2009-11-16
- **Final completion:** 2010-10-08
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00971425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00971425, "Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00971425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*